The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Early development of cyclin dependent kinase modulators.
K K Roy; E A Sausville (Profiled Author: Edward A Sausville)
Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Insstitute, 10 center Drive, Building no 10, Room no 6N, Bethesda, MD-20892-5680, USA. firstname.lastname@example.org
Current pharmaceutical design 2001;7(16):1669-87.
The protein kinase family presents remarkable opportunities for drug discovery and development targeting mainly to the ATP binding cleft. Cyclin-dependent kinases CDKs control the cell division in by controlling its sub phases. The regulation of CDKs is altered in a number of tumor types, and therefore CDKs are a particularly attractive target group of kinases with reference to proliferative disorders including cancer, but also extending to graft stenosis, and autoimmune disorders. Screening of chemical modulators of CDKs that modulate aberrant CDK activity might be beneficial for cancer therapy by directly inhibiting kinase activity, or influencing cell cycle "checkpoint" function, which is mediated through effects of exogenous cellular regulators of CDK activity. In this regard small molecule modulators such as flavopiridol and UCN-01 are in early clinical trials. Other more selective modulators of CDK function are being actively sought, and initial results with flavopiridol analogs, indirubins, paullones, and purine-based inhibitors will be considered.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Y A Elsayed; E A SausvilleThe oncologist 2001;6(6):517-37.
V Patel; A M Senderowicz; D Pinto; T Igishi; M Raffeld; L Quintanilla-Martinez; J F Ensley; E A Sausville; J S GutkindThe Journal of clinical investigation 1998;102(9):1674-81.
A M Senderowicz; E A SausvilleJournal of the National Cancer Institute 2000;92(5):376-87.
Appears in this Publication
Author of this Publication